The company’s lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. Recommended Story: Penny Stocks, Risk and …
More Minerva Neurosciences Inc (NASDAQ:NERV) Shares Sold by Morgan Stanley Videos